Skip to main content

Table 1 Clinical Trials of adoptive immunotherapy in ovarian cancer

From: Adoptive immunotherapy against ovarian cancer

Sponsor ID Condition Type of immunotherapy Primary outcome Secondary outcome Status
University Healt Network of Toronto NCT01883297 Recurrent, Platinum Resistant High Grade
Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Re-stimulated tumor-infiltrating lymphocytes (TILs) Number occurrences and severity of side effects Clinical response to treatment
Number of patients with an immunity and no immunity to the study treatment
Recruiting
National Cancer Institute NCT01174121 Metastatic cancer (digestive tract, urothelial, breast, ovarian/endometrial) Re-stimulated tumor-infiltrating lymphocytes (TILs) determine the ability of autologous TIL to mediate tumor regression / Recruiting
Harlev Hospital NCT02482090 Metastatic Ovarian Cancer Re-stimulated tumor-infiltrating lymphocytes (TILs) Determine the safety of the administration of TIL therapy including lymphodepleting chemotherapy and Interleukin-2 for patients with metastatic Ovarian Cancer Tumor related immunoresponses
ORR
OS
PFS
Recruiting
Mie University NCT02096614 Solid tumors (melanoma, head and neck cancer, ovarian cancer, esophageal cancer) MAGE-A4 Specific TCR Gene Transferred T Lymphocytes Confirm the toxicity profile
Confirm no replication competent retrovirus observed
Confirm no clonality is observed
Evaluate persistence and expansion of transferred TBI-1301
/ Recruiting
Mie University NCT02366546 Solid tumors (melanoma, head and neck cancer, ovarian cancer, synovial sarcoma, esophageal cancer) NY-ESO-1-specific TCR gene transduced T lymphocytes Toxicity profile confirmation
Confirm no replication competent retrovirus observed
Confirm no clonality is observed
Evaluate persistence and expansion of transferred TBI-1301
/ Recruiting
Memorial Sloan Kettering Cancer Center NCT00562640 Fallopian Tube, Ovarian, Primary Peritoneal Cancer Wilms’ tumor gene (WT1) peptide sensitized autologous T cells Safety and tolerability
Mean tolerated dose of autologous WT1 peptide-specific T cells
Quantitation of alterations in the concentration of peptide-specific T cells in the blood at defined intervals post infusion
Effects of the adoptively transferred T cells on the growth and progression of cancer
/ Active, not recruiting
Fred Hutchinson Cancer Research Center NCT00101257 Advanced ovarian cancer Autologous CD4+ Antigen Specific T Cell Clones • Safety and toxicity of autologous CD4-positive antigen-specific T cells
• Determine the duration of in vivo persistence of this drug in these patients.
• Determine the antitumor effect of this drug in these patients. Completed
Abramson Cancer Center of the University of Pennsylvania NCT01312376 Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Combined With Vaccine Boost and Bevacizumab • determine the feasibility and safety / Completed
Abramson Cancer Center of the University of Pennsylvania NCT02277392 Recurrent Ovarian Carcinoma, Fallopian Tube or Primary Peritoneal Cancer Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion • determine the feasibility and safety / Completed
Fred Hutchinson Cancer Research Center NCT00003887 Breast Cancer, Chronic Myeloproliferative Disorders,
Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Carcinoma, Sarcoma
Testicular Germ Cell Tumor
peripheral blood lymphocyte therapy • Determine the feasibility of donor lymphocyte infusion as adoptive immunotherapy / Completed
Cancer Research UK NCT01212887 Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes, aldesleukin, cyclophosphamide and fludarabine phosphate evaluate the feasibility
assess the toxicity of this regimen in these patients.
determine the dose required to give optimal survival of these cells in the circulation (recommended phase II dose).
assess whether MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes isolated from the circulation are functional.
determine the preliminary tumor response
evaluate the safety
Terminated
University of Washington NCT00228358 HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer
Recurrent Ovarian, Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
ex vivo-expanded HER2-specific T cells • Feasibility and Safety of infusing HER2 specific T cells Number of patients in whom the precursor frequency of antigen specific T cells is increased by 10-fold over baseline within one week after the last infusion
Number of patients in whom an immune response is demonstrated if baseline immune response was below detection
• HER2 specific CD4+ or CD8+ precursor frequencies
• Anti-tumor effects of HER2 specific T cells
• Persistence of T cell immune augmentation in vivo after adoptive transfer of HER2 specific T cells
Completed
Adaptimune NCT01567891 Recurrent Ovarian Epithelial cancer Citoreductive surgery followed by infusion with NYESO-1(C259) transduced autologous T cells. To determine the safety and tolerability of autologous redirected T cell therapy Tumor Response Recruiting